Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1313

Shown on this page

Current sort

Live official records

Conditions: Multiple Sclerosis
Interventions: MRI Contrast; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Lower-Carbohydrate Med-t-Diet, Low-Fat Med-t-Diet; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 21 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more

Conditions: Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions: CP-383; Drug
Lead sponsor: Tasca Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more

Conditions: High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 124
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more

Conditions: Metastatic Uveal Melanoma
Interventions: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Recurrent Pericarditis
Interventions: Not listed
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 7 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 29
States / cities: Anchorage, Alaska • Tucson, Arizona • La Jolla, California + 23 more

Conditions: Patellar Dislocation, Recurrent, Patellar Dislocation, Patellar Instability, Patellofemoral Dislocation, Patellofemoral Joint Dislocation, Patellofemoral Disorder
Interventions: Medial Patellofemoral Ligament (MPFL) Reconstruction; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 10 Years to 35 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Redwood City, California • Gainesville, Florida • Chicago, Illinois + 10 more

Conditions: Congenital Heart Disease, Congenital Vascular Disorder, Congenital Cardiomyopathy, Pregnancy Related
Interventions: Masimo Smart Wristband; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Interventions: TORL-1-23; Drug
Lead sponsor: TORL Biotherapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more

Conditions: Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Interventions: Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib, Pacritinib, Momelotinib; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Columbia, Maryland • New York, New York + 4 more

About this Cleveland Clinic institution page

What this page lists: ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Cleveland Clinic

Filter and sort this campus

Live official records

Central Vein Sign in Multiple Sclerosis Extension Study

Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

JUPITER 4.0 - Risk Factors for Failure of Isolated Medial Patellofemoral Ligament Reconstruction

Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

About this Cleveland Clinic institution page